Tirzepatide
| Sunan gama gari: | Tirzepatide |
| Cas No.: | 2023788-19-2 |
| Tsarin kwayoyin halitta: | Saukewa: C225H348N48O68 |
| Nauyin kwayoyin halitta: | 4813.45 g/mol |
| Jeri: | H-Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-gamma-Glu -(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Bayyanar: | Farin foda |
| Aikace-aikace: | Tirzepatide magani ne da ake nazari don yuwuwar amfani da shi wajen kula da nau'in ciwon sukari na 2. Yana cikin nau'in magungunan da ake kira diglucose-dependent insulinotropic peptide (GIP) da glucagon-like peptide-1 (GLP-1) agonists masu karɓa. Tezepatide yana aiki ta hanyar ƙarfafa masu karɓar GIP da GLP-1 a cikin jiki. Wadannan masu karɓa suna taka muhimmiyar rawa wajen daidaita matakan sukari na jini da metabolism. Ta hanyar kunna waɗannan masu karɓa, tezepatide yana ƙara samar da insulin kuma yana rage fitar da glucagon, hormone wanda ke haɓaka matakan sukari na jini. Hakanan yana rage zubar ciki kuma yana taimakawa daidaita matakan sukari na jini. Gwajin gwaji na asibiti sun nuna cewa tilsiparatide na iya sarrafa matakan sukari na jini yadda ya kamata a cikin marasa lafiya da ke da nau'in ciwon sukari na 2. An kuma gano shi don inganta asarar nauyi, wanda shine ƙarin fa'ida ga mutane da yawa masu fama da ciwon sukari na 2 waɗanda ke da wahalar kiyaye nauyin lafiya. Ɗaya daga cikin fa'idodin tezeparatide shine tsarin sa na yau da kullun na mako-mako, wanda zai iya ƙara dacewa da bin tsarin kulawa. Wannan na iya zama da fa'ida musamman ga mutanen da ke da wahalar bin tsarin jiyya na yau da kullun ko kuma waɗanda suka fi son tsarin jiyya mafi dacewa. Ya kamata a lura cewa tilsiparatide har yanzu yana cikin mataki na bincike kuma har yanzu ba a yarda da shi don amfani da hukumomin da suka dace ba. Ana buƙatar ƙarin bincike don ƙayyade amincinsa na dogon lokaci da ingancinsa da kuma gano duk wani sakamako mai illa. A taƙaice, tilsiparatide wani sabon magani ne da ake bincika don maganin ciwon sukari na 2. Ayyukansa biyu akan GIP da masu karɓar GLP-1 suna da yuwuwar haɓaka sarrafa glycemic da asarar nauyi. Koyaya, ana buƙatar ƙarin bincike kafin a iya ba da shawarar tilsiparatide azaman zaɓin jiyya ga masu ciwon sukari na 2. |
| Kunshin: | Bag foil aluminum ko aluminum TIN ko kamar yadda abokin ciniki ta bukatun |
| 1 | ƙwararrun masu ba da kayayyaki don peptide APIs daga China. |
| 2 | 16 samar da Lines tare da isasshen babban samar iya aiki tare da m farashin |
| 3 | Ana samun DMF tare da mafi amintattun takardu. |
A: Ee, za mu iya tattarawa azaman buƙatun ku.
A: LC gani da TT a gaba biya lokaci fĩfĩta.
A: Ee, da fatan za a samar da ƙayyadaddun ingancin ku, za mu bincika tare da R&D ɗin mu kuma muyi ƙoƙarin daidaita ƙayyadaddun ingancin ku.
Ku rubuta sakonku anan ku aiko mana
